The molecular diagnostic for infectious diseases market size is projected to reach US$ 17,614.44 million by 2030 from US$ 6,883.03 million in 2022. The market is expected to register a CAGR of 12.5% during 2022–2030. Molecular diagnostics for infectious diseases in personalized medicine is likely to remain a key trend in the market.
The factors driving the market include the surging prevalence of infectious diseases globally and the rising application of molecular diagnostics in veterinary infectious diseases. Furthermore, rising awareness of simulation education has created growth opportunities for the molecular diagnostic for infectious diseases market over the upcoming forecast period. Demand for gynecological devices is being driven by a rise in gynecological illnesses, including ovarian cancer, cervical cancer, uterine cancer, vaginal cancer, and vulvar cancer. According to the American Cancer Society's 2022 update, women are often diagnosed with endometrial cancer at the age of 60. However, diagnoses before the age of 45 are uncommon.
Public health is adversely affected by infectious diseases, causing morbidity, mortality, and economic burdens. Infectious diseases are on the rise, necessitating accurate and timely diagnosis to form the basis for effective disease management, treatment, and prevention. Diagnosing and monitoring multiple infections and diseases—including HIV, tuberculosis, hepatitis C, human papillomavirus screening for cervical cancer, and sexually transmitted infections, as well as outbreaks of infections—can be performed using molecular diagnostics techniques, laboratory-based assays, and point-of-care tests. According to an article published in the National Library of Medicine (NLM) in 2021, infectious diseases are a significant problem in most African countries due to limited healthcare resources and the high disease burden. More than 200 pathogens can cause fever in Nigeria, one of the most common reasons for visiting a healthcare facility. These pathogens include malaria parasites, Salmonella enterica and hemorrhagic viruses. It is impossible to detect life-threatening pathogens reliably with only culture results. Therefore, efficient molecular diagnostics are essential in areas with high infectious disease burdens.
Diagnostic technologies that can detect emerging infectious animal diseases at an early stage are essential for reducing economic losses associated with outbreaks of such diseases. Polymerase chain reaction (PCR) remains the most widely used molecular assay globally for detecting animal pathogens. Diagnostic methods of this type are easy to use, cost-effective, susceptible, and specific, with the ability to detect at a high volume.
Point-of-care diagnostics (POCDs) are simple, rapid, and portable diagnostic devices that can detect the disease status at the field level. In recent years, real-time PCR (qPCR) has been transitioned into a POCD platform. These fully automated platforms combine nucleic acid extraction, thermal cycling, and on-site reporting results. For instance, MiniLab from Enigma Diagnostics is a molecular diagnostic platform of 10–35 kg that is carried at the field level and used for validating African swine fever virus, avian influenza virus, classical swine fever virus, and foot-and-mouth disease virus for research purposes. Thus, molecular diagnostics methods such as PCR and qPCR to diagnose bacterial, viral, fungal, and parasitic infections in animals can replace the conventional methods such as serological, microscopic, and culture-based techniques.
Genetic and genomic research has led to the development of molecular diagnostic techniques that focus on nucleic acid detection, which provide new methods for detecting infectious diseases with a fast turnaround time. A molecular diagnostic technique detects multiple pathogens and analyzes drug-resistant genes of pathogens and pathogen homology analysis, making it an increasingly important tool for the early diagnosis of infectious diseases. Molecular diagnostic techniques and platforms are used in all areas of anatomic and clinical pathologies. DNA or RNA sequences associated with disease, including single nucleotide polymorphism, deletions, rearrangements, and insertions, can be detected via molecular diagnostic tests. Conventionally, CT scans, hematological tests, and reverse transcription-PCR (RT-PCR) were used for testing. Due to growing infectious diseases, the need for rapid, precise testing platforms surged to overcome the disadvantages of conventional testing. Collaborative efforts by scientific communities in different countries to manage infectious diseases and reduce the extent of mortality have benefited the overall molecular tools and diagnosis landscape, which will likely create significant opportunities for the molecular diagnostics for infectious diseases market in the future.
Key segments that contributed to the derivation of the molecular diagnostic for infectious diseases market analysis are product and end user.
The geographic scope of the molecular diagnostic for infectious diseases market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
The North America molecular diagnostics for infectious diseases market has been segmented into the US, Canada, and Mexico. The increasing acceptance of technologically advanced products, a rise in research and development activities, the presence of large healthcare businesses, and the growing use of molecular diagnostics kits for infectious disease diagnosis are among the key factors propelling the growth of the molecular diagnostics for infectious diseases market in North America. The molecular diagnostics for infectious diseases market growth in the US is primarily driven by the increasing prevalence of infectious disease, rising geriatric population, and multiple product launches by key players. Aging is a prominent risk factor for renal diseases. According to a study published by the Population Reference Bureau in 2020, the population of individuals aged 65 and above was 55 million in the US in 2020, and the number is expected to hike up to 95 million by 2060. Regulatory agencies in the US are devising favorable policies for the development of point-of-care (POC) products for the diagnosis and treatment of various indications.
The regional trends and factors influencing the Molecular Diagnostic for Infectious Diseases Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Molecular Diagnostic for Infectious Diseases Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 6.88 Billion |
| Market Size by 2030 | US$ 17.61 Billion |
| Global CAGR (2022 - 2030) | 12.5% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Molecular Diagnostic for Infectious Diseases Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Molecular Diagnostic for Infectious Diseases Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The Molecular Diagnostic for Infectious Diseases Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the molecular diagnostic for infectious diseases market are listed below:
The “Molecular Diagnostic for Infectious Diseases Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
The List of Companies - Molecular Diagnostics for Infectious Diseases Market
The factors driving the market include surging prevalence of infectious disease globally and rising application of molecular diagnostics in veterinary infectious diseases. However, limitations associated with molecular testing hinders the market growth.
F.Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc, bioMerieux SA, Danaher Corp, Hologic Inc, Siemens Healthineers AG, Bruker Corp, Molzym GmbH & Co KG, and DiaSorin SpA.
North America dominated the molecular diagnostic for infectious diseases market in 2022
The market is expected to register a CAGR of 12.5% during 2022–2030.
Molecular diagnostics for infectious diseases in personalized medicine is likely to remain a key trend in the market.